These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37210524)

  • 1. Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study.
    Kishimoto S; Higashi Y; Imai T; Eguchi K; Fukumoto K; Tomiyama H; Maemura K; Tanaka A; Node K;
    Cardiovasc Diabetol; 2023 May; 22(1):119. PubMed ID: 37210524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.
    Tanaka A; Murohara T; Taguchi I; Eguchi K; Suzuki M; Kitakaze M; Sato Y; Ishizu T; Higashi Y; Yamada H; Nanasato M; Shimabukuro M; Teragawa H; Ueda S; Kodera S; Matsuhisa M; Kadokami T; Kario K; Nishio Y; Inoue T; Maemura K; Oyama J; Ohishi M; Sata M; Tomiyama H; Node K;
    Cardiovasc Diabetol; 2016 Sep; 15(1):133. PubMed ID: 27619983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.
    Tanaka A; Shimabukuro M; Okada Y; Sugimoto K; Kurozumi A; Torimoto K; Hirai H; Node K;
    Cardiovasc Diabetol; 2020 Jun; 19(1):85. PubMed ID: 32534578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial.
    Tanaka A; Sata M; Okada Y; Teragawa H; Eguchi K; Shimabukuro M; Taguchi I; Matsunaga K; Kanzaki Y; Yoshida H; Ishizu T; Ueda S; Kitakaze M; Murohara T; Node K;
    Eur Heart J Cardiovasc Pharmacother; 2023 Feb; 9(2):165-172. PubMed ID: 36308299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term observation of estimated fluid volume reduction after the initiation of ipragliflozin in patients with type 2 diabetes mellitus: a sub-analysis from a randomized controlled trial (PROTECT).
    Tanaka A; Imai T; Toyoda S; Sugimoto K; Yoshida R; Furuta M; Node K;
    Diabetol Metab Syndr; 2023 Jul; 15(1):152. PubMed ID: 37415229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.
    Tanaka M; Yamakage H; Inoue T; Odori S; Kusakabe T; Shimatsu A; Satoh-Asahara N
    Intern Med; 2020; 59(5):601-609. PubMed ID: 32115517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study.
    Maruhashi T; Higashi Y; Kihara Y; Yamada H; Sata M; Ueda S; Odawara M; Terauchi Y; Dai K; Ohno J; Iida M; Sano H; Tomiyama H; Inoue T; Tanaka A; Murohara T; Node K;
    Cardiovasc Diabetol; 2016 Sep; 15(1):134. PubMed ID: 27624168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study.
    Kashiwagi A; Takahashi H; Ishikawa H; Yoshida S; Kazuta K; Utsuno A; Ueyama E
    Diabetes Obes Metab; 2015 Feb; 17(2):152-60. PubMed ID: 25347938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.
    Han KA; Chon S; Chung CH; Lim S; Lee KW; Baik S; Jung CH; Kim DS; Park KS; Yoon KH; Lee IK; Cha BS; Sakatani T; Park S; Lee MK
    Diabetes Obes Metab; 2018 Oct; 20(10):2408-2415. PubMed ID: 29862619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of ipragliflozin on blood pressure in patients with type 2 diabetes: insights from the randomized PROTECT trial.
    Saito Y; Tanaka A; Imai T; Nakamura I; Kanda J; Matsuhisa M; Uehara H; Kario K; Kobayashi Y; Node K;
    Hypertens Res; 2024 Jan; 47(1):168-176. PubMed ID: 37964067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
    Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
    Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
    Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
    Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study.
    Nakamura I; Maegawa H; Tobe K; Uno S
    Adv Ther; 2019 Apr; 36(4):923-949. PubMed ID: 30767112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolomic analysis of serum samples from a clinical study on ipragliflozin and metformin treatment in Japanese patients with type 2 diabetes: Exploring human metabolites associated with visceral fat reduction.
    Tsukagoshi-Yamaguchi A; Koshizaka M; Ishibashi R; Ishikawa K; Ishikawa T; Shoji M; Ide S; Ide K; Baba Y; Terayama R; Hattori A; Takemoto M; Ouchi Y; Maezawa Y; Yokote K;
    Pharmacotherapy; 2023 Dec; 43(12):1317-1326. PubMed ID: 37772313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.
    Wilding JP; Ferrannini E; Fonseca VA; Wilpshaar W; Dhanjal P; Houzer A
    Diabetes Obes Metab; 2013 May; 15(5):403-9. PubMed ID: 23163880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor.
    Hwang YC; Kim JH; Lee BW; Lee WJ
    Diabetes Metab J; 2019 Dec; 43(6):898-905. PubMed ID: 31237132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.
    Shigiyama F; Kumashiro N; Miyagi M; Ikehara K; Kanda E; Uchino H; Hirose T
    Cardiovasc Diabetol; 2017 Jul; 16(1):84. PubMed ID: 28683796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study.
    Kitazawa M; Katagiri T; Suzuki H; Matsunaga S; H Yamada M; Ikarashi T; Yamamoto M; Furukawa K; Iwanaga M; Hatta M; Fujihara K; Yamada T; Tanaka S; Sone H
    Diabetes Obes Metab; 2021 Mar; 23(3):811-821. PubMed ID: 33416200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.
    Nagai Y; Ohta A; Sada Y; Kato H; Tanaka Y
    Expert Opin Pharmacother; 2017 Jan; 18(1):13-17. PubMed ID: 27841020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double-blind, phase 3 trial.
    Kaku K; Isaka H; Sakatani T; Toyoshima J
    Diabetes Obes Metab; 2019 Oct; 21(10):2284-2293. PubMed ID: 31173455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.